

CLAIMS

1. An implant, which includes a body of non-resorbable bioactive material, with zones of resorbable bioactive material located in the body of non-resorbable material, and with the sizes of a major proportion of the zones of resorbable material being from 10 to 500 microns.

2. An implant according to Claim 1, wherein the non-resorbable bioactive material is hydroxyapatite, while the resorbable material is tricalcium phosphate.

3. An implant according to Claim 2, wherein substantially all of the zones of tricalcium phosphate are of the same size.

4. An implant according to Claim 3, wherein the zones of the tricalcium phosphate are randomly dispersed throughout the hydroxyapatite body, with some of the zones being located at the surface of the body.

5. An implant according to any one of Claims 2 to 4 inclusive, wherein the size of the zones is from 10 to 300 microns.

6. An implant according to any one of Claims 2 to 5 inclusive, wherein the proportion of hydroxyapatite to tricalcium phosphate in the implant is from 4:1 to 2:3, on a mass basis.

7. An implant according to any one of Claims 2 to 6 inclusive, wherein macropores are provided in the body.

8. An implant according to claim 7, wherein the macropores are substantially spherical, with at least some

10009214-10301

of the macropores being interconnected by being coalesced together.

~~9.~~ An implant according to Claim 8, wherein the macropores are from 100 to 2000 microns in size.

5 ~~10.~~ An implant according to Claim 8 or Claim 9, wherein at least a majority of the macropores are of substantially the same size, and wherein the macropores occupy from 20% to 80% of the total volume of the body.

10 ~~11.~~ An implant according to any one of Claims 7 to 10 inclusive, wherein the macropores are randomly interspersed throughout the body, so that the body has a network of interconnected coalesced rounded inner macroporous spaces.

15 ~~12.~~ An implant according to any one of Claims 8 to 11 inclusive, wherein the body is provided with surface concavities.

~~13.~~ An implant according to Claim 12, wherein the surface concavities are rounded, having diameters of from 100 to 2000 microns, and depths of 500 to 1000 microns.

20 ~~14.~~ An implant according to Claim 12 or Claim 13, wherein the surface concavities are hemispherical and are interconnected with the macropores by being coalesced therewith.

25 ~~15.~~ An implant according to any one of Claims 2 to 14 inclusive, wherein micropores are provided in the body, with the micropores being randomly interspersed throughout the body.

~~16.~~ An implant according to Claim 15, wherein the micropores are all of substantially the same size, and are smaller than 50 microns

1000924 426001

17. An implant according to Claim 15 or Claim 16, wherein the micropores occupy 60% or less of the total volume of the body, excluding the volume occupied by the macropores.

5 18. A method of making an implant, which method includes

mixing a non-resorbable bioactive material in powder form with a thermoplastic binder at elevated temperature, to produce a first powder/binder mixture;

10 comminuting the first powder/binder mixture to obtain a first granular mixture having granules or particles with sizes from 10 to 500 microns;

mixing a resorbable bioactive material in powder form with a thermoplastic binder at elevated temperature, to produce a second powder/binder mixture;

15 comminuting the second powder/binder mixture to obtain a second granular mixture having granules or particles with sizes from 10 to 500 microns;

20 combining the first and second granular mixtures to form a combined mixture;

optionally, mixing the combined mixture with fugitive phase particles which are heat decomposable, with the fugitive phase particles having sizes of 100 to 2000 microns;

25 pressing or compacting the resultant mixture into a green compact or body;

when the fugitive phase particles are present, heating the green compacts or bodies to above the decomposition temperature of the fugitive phase particles; and

30 sintering the resultant green body, to obtain an implant.

19. A method according to Claim 18, wherein the non-resorbable bioactive material is hydroxyapatite, while the resorbable material is tricalcium phosphate.

1000924 "110301
426001

20. A method according to Claim 19, wherein the temperature at which the mixing of the hydroxyapatite powder and the tricalcium phosphate powder with the thermoplastic binder to produce the first and second powder/binder mixtures takes place, is about 120°C, and wherein the comminution of the first and second powder/binder mixtures is effected by crushing the mixtures, and sieving them to the required granule or particle size.

21. A method according to Claim 19 or Claim 20, wherein the fugitive phase particles are present and are spherical stearic acid particles having a size range of 500 to 1000 microns.

22. A method according to Claim 21, wherein the mass proportion of the combined mixture to fugitive phase particles is about 1,27:1 by mass, to obtain an implant having a macropore volume of approximately 60% of the total implant volume.

~~23.~~ A method according to Claim 21 or Claim 22, wherein the green compacts are heated to about 500°C, to allow melting and decomposition of the stearic acid, thereby forming, in the green compacts or bodies, interconnected macropores produced by the decomposition of the stearic acid particles.

~~24.~~ A method according to Claim 23, wherein, to obtain a microporosity level or volume of 40% of the residual solid component of the implant, the sintering is effected at about 1100°C for one hour.

~~25.~~ A novel implant, substantially as described and illustrated herein.

~~26.~~ A novel method of making an implant,
substantially as described and illustrated herein.

1009214-110301
T080T-426000T